CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 疗法治疗中枢神经系统淋巴瘤的进展
英文原题：Advances in CAR-T therapy for central nervous system lymphoma.
查看英文原题
Advances in CAR-T therapy for central nervous system lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞 疗法改变了复发/难治性 B 细胞淋巴瘤的治疗方法，但其在中枢神经系统淋巴瘤中的最初使用因安全问题和有限的疗效而受到阻碍。目前的数据来自小型、异质性试验，关于神经毒性缓解、最佳治疗时机、长期反应持久性和预测生物标志物等尚未解决的问题，阻碍了广泛的临床实施。这篇叙述性综述系统地整合了同行评审的临床试验、真实世界的回顾性数据集和临床前机制研究，总结了 CAR-T 在 PCNSL 和 SCNSL 患者中的疗效和安全性。
展开英文摘要原文
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the management of relapsed/refractory B-cell lymphomas, yet its initial use in central nervous system lymphoma has been hampered by safety concerns and limited efficacy. Current data are derived from small, heterogeneous trials, with unresolved questions regarding neurotoxicity mitigation, optimal treatment timing, long-term response durability, and predictive biomarkers, precluding widespread clinical implementation.
This narrative review systematically integrates peer-reviewed clinical trials, real-world retrospective datasets and preclinical mechanistic investigations to summarize the efficacy and safety profile of CAR-T in patients with PCNSL and SCNSL.
论文信息
- 作者
- Feng X、Yang J、Xu X、Kai W、Huang Y、Zhang S、Su L、Zhang L
- 第一作者单位
- Department of Hematology, The Fourth People's Hospital of Jinan Affiliated to Shandong Second Medical University, Jinan, China.China
- 通讯作者单位
- Shandong Provincial Key Medical and Health Laboratory of Blood Ecology and Biointelligence, Jinan Key Laboratory of Medical Cell Bioengineering, Science and Technology Innovation Center, The Fourth People's Hospital of Jinan Affiliated to Shandong Second Medical University, Jinan, China.China
- 文献类型
- 综述
- 期刊
- Frontiers in immunology2026
- 原文标识
- PubMed 42699265 · DOI 10.3389/fimmu.2026.1858455
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →